The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Subscribe To Our Newsletter & Stay Updated
